MHRA issues consent for RedHill Bioharma’s Yeliva trial
The study will assess the potential of the drug in patients hospitalised with severe SARS-CoV-2 infection and pneumonia
Read More
Tag: Yeliva
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
